Back to the main directory
Company Analysis / Equity
- ICAD: High-Margin Services Biz Driving Strong Top-Line Growth by Zacks
- ICAD: Q1 Revenue Soft. Look For Turnaround in NMSC, Tomo Launch by Zacks
- ICAD: Q4 Mostly Inline. 1H 2016 May Be Soft, Look for Pick Up in 2H on Tomo Contribution by Zacks
- ICAD: Solid Revenue Rebound, Skin Biz Showing Signs of Life by Zacks
- ICAD: Therapy Drops On Reimbursement Issue. Detection Takes The Reins Going Into 2016 by Zacks
- ICAD: Tomosynthesis, DermEbx Should Be Major Catalysts in 2015 by Zacks
- ICAD: Therapy Revenue +47%, Expect Momentum To Carry Into 2014 by Zacks
- ICAD: Strong Detection Revenue, Skin Utilization by Zacks
- LPCN: Early Start to Tlando Validation Trial by Zacks
- LPCN: Files NDA for LPCN 1021 with FDA Approval on Track for 2016… by Zacks
- LPCN: Remains on Track for Mid-2016 LPCN 1021 Approval by Zacks
- GNMX: Anti-LIGHT Candidate Could Be Fast-Moving, Represents $300M+ Market Opportunity by Zacks
- GNMX: Efficacy Through 10 Months, Add l Studies Commencing by Zacks
- GNMX: Highly Promising Prelim MDGN- 201 Data by Zacks
- GNMX: NFC-1 ADHD Phase 2/3 Data, Expected Later This Year, Could Be Needle-Mover by Zacks
- GNMX: Positive TARGET EPO Data Through 7 Months by Zacks
- GNMX: Q4 Call, Continued Promising Trial Results by Zacks
- GNMX: Several Upcoming Milestones Including NFC-1 ADHD Phase 2/3 Data by Zacks
- GNMX: Waiting On Edge of Seat, NFC-1 Data Later This Year by Zacks
- Q1 Results - Detection Segment Returns To Growth, Therapy Up 64%! by Zacks
- Q3 Results Beat on Revenue, GM, Expenses, EPS by Zacks
- Q4 Results. IORT Reimbursement Issue Impacting Revenue Ramp by Zacks
- Reports 2015 results with lower cash burn rate due to completion of Phase 3 trial for LPCN 1021; cash balance near 2x FY16 estimated expenses. by Zacks
- LPCN: Initiating coverage of Lipocine, Inc., developing an oral testosterone replacement therapy currently in Phase 3 by Zacks
- LPCN: Phase 3 SOAR Completed And Still On Track To File The NDA In The 2nd Half Of 2015 by Zacks